As of close of business last night, PTC Therapeutics Inc’s stock clocked out at $30.88, down -1.34% from its previous closing price of $31.30. In other words, the price has decreased by -$0.42 from its previous closing price. On the day, 740930 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
To gain a deeper understanding of PTCT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.97 and its Current Ratio is at 2.02.
On December 08, 2023, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $37.
Oppenheimer Upgraded its Perform to Outperform on October 30, 2023, while the target price for the stock was maintained at $165.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 30 ’24 when Boulding Mark Elliott sold 794 shares for $27.25 per share. The transaction valued at 21,637 led to the insider holds 71,189 shares of the business.
Almstead Neil Gregory sold 618 shares of PTCT for $16,841 on Jan 30 ’24. The CHIEF TECHNICAL OPS OFFICER now owns 61,202 shares after completing the transaction at $27.25 per share. On Jan 30 ’24, another insider, Pauwels Eric, who serves as the CHIEF BUSINESS OFFICER of the company, sold 366 shares for $27.25 each. As a result, the insider received 9,974 and left with 44,181 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTCT now has a Market Capitalization of 2.37B and an Enterprise Value of 3.72B. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.52. Its current Enterprise Value per Revenue stands at 3.97 whereas that against EBITDA is -11.26.
Stock Price History:
Over the past 52 weeks, PTCT has reached a high of $59.84, while it has fallen to a 52-week low of $17.53. The 50-Day Moving Average of the stock is 27.41, while the 200-Day Moving Average is calculated to be 31.65.
Shares Statistics:
It appears that PTCT traded 1.11M shares on average per day over the past three months and 1M shares per day over the past ten days. A total of 75.71M shares are outstanding, with a floating share count of 73.66M. Insiders hold about 3.85% of the company’s shares, while institutions hold 110.51% stake in the company. Shares short for PTCT as of Feb 15, 2024 were 10.38M with a Short Ratio of 9.34, compared to 9.97M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 13.71% and a Short% of Float of 18.55%.
Earnings Estimates
As of right now, 13 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$1.25 for the current quarter, with a high estimate of -$0.56 and a low estimate of -$1.93, while EPS last year was -$1.88. The consensus estimate for the next quarter is -$1.43, with high estimates of -$0.79 and low estimates of -$1.95.
Analysts are recommending an EPS of between -$3.7 and -$8.45 for the fiscal current year, implying an average EPS of -$6.11. EPS for the following year is -$5.01, with 14 analysts recommending between -$1.95 and -$9.16.
Revenue Estimates
In the current quarter, 10 analysts expect revenue to total $170.36M. It ranges from a high estimate of $209.6M to a low estimate of $143.5M. As of the current estimate, PTC Therapeutics Inc’s year-ago sales were $220.38M, an estimated decrease of -22.70% from the year-ago figure. For the next quarter, 10 analysts are estimating revenue of $149.01M, a decrease of -30.30% less than the figure of -$22.70% in the same quarter last year. There is a high estimate of $169.37M for the next quarter, whereas the lowest estimate is $136.5M.
A total of 14 analysts have provided revenue estimates for PTCT’s current fiscal year. The highest revenue estimate was $675.8M, while the lowest revenue estimate was $446M, resulting in an average revenue estimate of $595.65M. In the same quarter a year ago, actual revenue was $937.82M, down -36.50% from the average estimate. Based on 14 analysts’ estimates, the company’s revenue will be $608.6M in the next fiscal year. The high estimate is $757.29M and the low estimate is $332.8M. The average revenue growth estimate for next year is up 2.20% from the average revenue estimate for this year.
